Yazar "Kocazeybek, Bekir" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim
    Yayın
    COVID-19 geçiren, CoronaVac ve BNT162b2 aşı olan bireylerde hümoral immün yanıtın değerlendirilmesi
    (Harran Üniversitesi, 2022) Gareayaghi, Nesrin; Dinç, Harika Öykü; Özbey, Doğukan; Akçin, Rüveyda; Daşdemir, Ferhat; Akkuş, Seher; Eryiğit, Önder Yüksel; Kocazeybek, Bekir
    Amaç: Günümüzde COVID-19 aşılaması ya da geçirilmiş enfeksiyon sonrasında humoral immün yanıtı değerlendirmek amacıyla pek çok immünolojik test yöntemi kullanılmaktadır. Çalışmamızda CoronaVac, veya BNT162b2 ile aşılanan ve COVID-19 geçiren kişilerde SARS-CoV-2 humoral immün yanıtı üç farklı immünolojik test yöntemiyle değerlendirmeyi amaçladık. Materyal ve metod: COVID-19 tanısı alan 30, CoronaVac aşısı olan 35 ve BNT162b2 aşısı olan 35 kişinin 28 gün sonra alınan serum örnekleri çalışmaya dahil edilmiştir. SARS-CoV 2’nin spike proteini S1 alt biriminin reseptör bağlayıcı bölgesine (RBD) karşı nötralize edici antikorlar üç farklı prensibe yönelik (CMIA, ELISA, LFA) antikor testleri ile (ARCHITECT IgG II Quant test, Abbott, USA/SARS-CoV-2 NeutraLISA, Euroimmun, Lübeck, Almanya/ NeutraXpress™, JOYSBIO Biotechnology Co. Ltd., Tianjin China) çalışıldı. Verilerin istatistiksel değerlendirmesinde IBM SPSS 21.0 paket programı kullanıldı. Bulgular: Tüm olguların SARS-CoV-2 kantitatif antikor titreleri 2635,150 (391,1-8053,425) AU/mL olarak saptandı. Gruplar arasındaki istatistiksel değerlendirmede, COVID-19 geçiren ve BNT162b2 aşısı olan kişilerin SARS-CoV-2 kantitatif antikor titreleri, CoronaVac ile aşılı gruba kıyasla anlamlı olarak yüksek saptandı (p<0.001). SARS-CoV-2 nötralizan antikor inhibisyon yüzdesi tüm olgularda %88,4 (32,9-98,8) iken, COVID-19 geçiren ve BNT162b2 aşısı olanlarda anlamlı olarak yüksek saptandı (p<0.001). Lateral-flow yöntemine göre bağlanan total antikor varlığı 75 (%75) kişide pozitif olarak saptanırken, nötralizan antikor 60 (%60) kişide pozitif olarak saptandı. Sonuç: Çalışmamızın sonuçlarına göre, enfeksiyon ve aşılama sonrası SARS-CoV-2’ye spesifik humoral immün yanıtın geliştiği görülmektedir. Ayrıca, immünolojik yöntemlerle humoral immün yanıtın değerlendirilmesinde, duyarlılığı ve özgüllüğü yüksek olan testlerin tercih edilmesi gerektiğini düşünmekteyiz.
  • Küçük Resim
    Yayın
    Evaluation of seropositivity developed against specific antigens of helicobacter pylori in neurodegenerative diseases
    (Turkish Neuropsychiatric Society, 2026) Akçin, Rüveyda; Tütüncü, Melih; Karagöz Sakallı, Nazan; Apaydın, Hülya; Bozluolçay, Melda; Can, Günay; Soysal, Aysun; Sirekbasan, Serhat; Dinç, Harika Öykü; Sarıbaş, Suat; Kocazeybek, Bekir
    Introduction: It is suggested that Helicobacter pylori (Hp) can reach the brain via the oral-nasal-olfactory route, through Hp-infected monocytes in the disrupted blood-brain barrier (BBB), or through a rapid retrograde neural network leading to neurodegeneration from the gastrointestinal tract (GIS) and may lead to neurodegenerative diseases such as Alzheimer’s (AD), Parkinson’s (PD) and Multiple sclerosis (MS). In this study, we aimed to evaluate the possible immunopathogenesis relationship between Hp-specific antigens and neurodegenerative diseases by determining the frequency of seropositivity against different specific antigens of Hp in diseases such as AD, PD and MS. Methods: In our cross-sectional, retrospective case-control study, the immunoreactivity frequencies of Hp-specific and non-specific CagA (p120), VacA (p95), p75, FSH (p67), UreB (p66), HSP homolog (p57), flagellin (p54), p50, p41, p33, OMP (p30), UreA (p29), p26, OMP (p19), p17 antigens were determined by Western Blot method in 36 AD, 35 PD, 91 MS cases with Hp-IgG reactivity, and 55 controls without a neurodegenerative/demyelinating by ELISA method. Results: No significant difference was found between the immunoreactivity frequencies of Hp antigens between AD and control groups (p>0.05). In the multivariate logistic analysis performed for PD cases, age ≥ 50 and immunoreactivity frequency of p19 were found to be independent risk factors (OR: 36.752, p<0.05) (OR: 5.570, p<0.05). In MS cases, immunoreactivity frequency of p17 antigen was found to be a risk factor (OR: 2.646, p<0.05). In addition, the mean level of Hp-IgG reactivity was found to be negatively associated with MS development (indicating an inverse correlation) in the control group compared to the MS group (OR: 0.585, p < 0.05). Furthermore, logistic regression analysis in the total study group revealed that the immunoreactivity frequency of the p17 antigen was identified as a risk factor for MS (OR: 2.438, p<0.05). Conclusion: Our data on AD cases are insufficient. In PD cases, the significantly higher frequency of immunoreactivity to the Hp-p19 antigen in individuals aged ≥50 years (OR=5.570) is noteworthy. In the MS group, the significantly high detection of Hp p17 antigen and its presence as a risk factor (OR=2.646), and the significantly high detection of p26 antigen suggest the relationship between these antigens and the MS development process. However, it is a fact that new and many prospective cohort-based case-control studies are needed to reveal this more clearly.
  • Küçük Resim
    Yayın
    Evaluation of the diagnostic performance of a SARS-CoV-2 and Influenza A/B combo rapid antigen test in respiratory samples
    (MPDI, 2023) Dinç, Harika Öykü; Karabulut, Nuran; Alaçam, Sema; Kırkoyun Uysal, Hayriye; Daşdemir, Ferhat Osman; Önel, Mustafa; Tuyji Tok, Yeşim; Sirekbasan, Serhat; Agaçfidan, Ali; Gareayaghi, Nesrin; Çakan, Hüseyin; Eryiğit, Önder Yüksel; Kocazeybek, Bekir
    This study aimed to evaluate the performance characteristics of a rapid antigen test developed to detect SARS-CoV-2 (COVID-19), influenza A virus (IAV), and influenza B virus (IBV) (flu) compared with those of the real-time reverse transcription-polymerase chain reaction (rRT-PCR) method. One hundred SARS-CoV-2, one hundred IAV, and twenty-four IBV patients whose diagnoses were confirmed by clinical and laboratory methods were included in the patient group. Seventy-six patients, who were negative for all respiratory tract viruses, were included as the control group. The Panbio™ COVID-19/Flu A&B Rapid Panel test kit was used in the assays. The sensitivity values of the kit were 97.5%, 97.9%, and 33.33% for SARS-CoV-2, IAV, and IBV, respectively, in samples with a viral load below 20 Ct values. The sensitivity values of the kit were 16.7%, 36.5%, and 11.11% for SARS-CoV-2, IAV, and IBV, respectively, in samples with a viral load above 20 Ct. The kit’s specificity was 100%. In conclusion, this kit demonstrated high sensitivity to SARS-CoV-2 and IAV for viral loads below 20 Ct values, but the sensitivity values were not compatible with PCR positivity for lower viral loads over 20 Ct values. Rapid antigen tests may be preferred as a routine screening tool in communal environments, especially in symptomatic individuals, when diagnosing SARS-CoV-2, IAV, and IBV with high caution.